Using Panorama to analyse TP53 mutations at the pan-cancer level enables the identification of therapeutic targets and prognostic evaluation for specific cancer types, thereby uncovering tissue-dependent heterogeneity in TP53 mutation mechanisms. The gene discussed is TP53; the disease is cancer.